Search Results - "Maus, Stephan"

LeTID mitigation via an adapted firing process in p‐type PERC cells from SMART cast‐monocrystalline, Czochralski and high‐performance multicrystalline silicon.

Authors: Maischner, Felix Maus, Stephan Greulich, Johannes et al.

Source: Progress in Photovoltaics. Feb2022, Vol. 30 Issue 2, p123-131. 9p.

21.4% efficient SMART mono-Si PERC solar cells with adapted firing process for LeTID mitigation.

Authors: Maischner, Felix Maus, Stephan Greulich, Johannes et al.

Source: AIP Conference Proceedings. 2022, Vol. 2487 Issue 1, p1-5. 5p.

Comprehensive Model for Charge Carrier Recombination in Czochralski‐Grown Silicon Due to Oxygen Precipitation in Industrial Solar Cell Manufacturing.

Authors: Maus, Stephan Mack, Sebastian Schön, Jonas et al.

Source: Solar RRL. Feb2023, Vol. 7 Issue 4, p1-21. 21p.

SMART Cast‐Monocrystalline p‐Type Silicon Passivated Emitter and Rear Cells: Efficiency Benchmark and Bulk Lifetime Analysis.

Authors: Maus, Stephan Maischner, Felix Riepe, Stephan et al.

Source: Solar RRL. Apr2021, Vol. 5 Issue 4, p1-6. 6p.

Proof-of-Concept Study of the NOTI Chelating Platform: Preclinical Evaluation of 64Cu-Labeled Mono- and Trimeric c(RGDfK) Conjugates.

Authors: Martin, Sebastian Maus, Stephan Stemler, Tobias et al.

Source: Molecular Imaging & Biology. 2021, Vol. 23 Issue 1, p95-108. 14p.

Outcome and safety of single-dose docetaxel–augmented targeted radionuclide therapy using [¹⁷⁷Lu]Lu-PSMA-617 radioligand therapy in treatment-refractory mCRPC: preliminary evidence from a pilot experience.

Authors: Ebert, Niklas Rosar, Florian Burgard, Caroline et al.

Source: EJNMMI Research. 3/16/2026, Vol. 16 Issue 1, p1-9. 9p.

Dosimetric analysis reveals rapid clearance and low absorbed dose of [¹⁷⁷Lu]Lu-PSMA-617 in non-prostate cancers with high PSMA expression.

Authors: Khreish, Fadi Rosar, Florian Burgard, Caroline et al.

Source: EJNMMI Research. 2/24/2026, Vol. 16 Issue 1, p1-10. 10p.

Expanding the scope of PSMA-RLT: evaluating treatment in challenging mCRPC patients with poor performance status (ECOG 3).

Authors: Bastian, Moritz B. Wörl, Benedikt Blickle, Arne et al.

Source: European Journal of Nuclear Medicine & Molecular Imaging. Nov2025, Vol. 52 Issue 13, p4893-4901. 9p.

Optimized production, quality control, biological evaluation and PET/CT imaging of 68Ga-PSMA-617 in breast adenocarcinoma model.

Authors: Sharifi, Mehdi Yousefnia, Hassan Bahrami-Samani, Ali et al.

Source: Radiochimica Acta; May2017, Vol. 105 Issue 5, p399-407, 9p

Labelling of commercially available human serum albumin kits with ⁶⁸Ga as surrogates for ^99mTc-MAA microspheres

Authors: Maus, Stephan Buchholz, Hans-Georg Ament, Stephan et al.

Source: Applied Radiation & Isotopes. Jan2011, Vol. 69 Issue 1, p171-175. 5p.

Subjects: Radiolabeling, Serum albumin, Gallium isotopes, Technetium isotopes, Positron emission tomography, Radiochemical research, Microspheres

Tolerability of PSMA radioligand therapy in metastatic prostate cancer patients with baseline mild to moderate leukopenia.

Authors: Bastian, Moritz B. Speicher, Tilman Blickle, Arne et al.

Source: EJNMMI Research. 7/6/2025, Vol. 15 Issue 1, p1-9. 9p.

Zirconium-89-based PSMA PET/CT with delayed imaging for early detection of biochemical recurrence in prostate cancer patients with PSA ≤ 0.2 ng/mL: A feasibility study.

Authors: Speicher, Tilman Latell, Simon Blickle, Arne et al.

Source: European Journal of Nuclear Medicine & Molecular Imaging. Apr2026, p1-9. 9p.

Comparison of mCRPC [¹⁷⁷Lu]Lu-PSMA-617 radioligand therapy with and without concurrent enzalutamide medication in a real-world setting.

Authors: Rosar, Florian Khreish, Fadi Burgard, Caroline et al.

Source: European Journal of Nuclear Medicine & Molecular Imaging. Apr2026, Vol. 53 Issue 5, p3034-3041. 8p.

Safety of PSMA radioligand therapy in mCRPC patients with preexisting moderate to severe thrombocytopenia.

Authors: Bastian, Moritz B. Sieben, Maike Blickle, Arne et al.

Source: European Journal of Nuclear Medicine & Molecular Imaging. Mar2025, Vol. 52 Issue 4, p1271-1277. 7p.

Development of a homotrimeric PSMA radioligand based on the NOTI chelating platform.

Authors: Martin, Sebastian Schreck, Moritz-Valentin Stemler, Tobias et al.

Source: EJNMMI Radiopharmacy & Chemistry. 12/11/2024, Vol. 9 Issue 1, p1-23. 23p.

The radiolabeling of [¹⁶¹Tb]Tb-PSMA-617 by a novel radiolabeling method and preclinical evaluation by in vitro/in vivo methods.

Authors: Uygur, Emre Sezgin, Ceren Parlak, Yasemin et al.

Source: Journal of Radioanalytical & Nuclear Chemistry. Dec2024, Vol. 333 Issue 12, p6403-6413. 11p.

Efficacy and safety of rechallenge [¹⁷⁷Lu]Lu-PSMA-617 RLT after initial partial remission in patients with mCRPC: evaluation of a prospective registry (REALITY study).

Authors: Rosar, Florian Schuler, Joelle Burgard, Caroline et al.

Source: European Journal of Nuclear Medicine & Molecular Imaging. Nov2024, Vol. 51 Issue 13, p4151-4162. 12p.

Analysis of Molecular Imaging Biomarkers Derived from [ 18 F]FDG PET/CT in mCRPC: Whole-Body Total Lesion Glycolysis (TLG) Predicts Overall Survival in Patients Undergoing [ 225 Ac]Ac-PSMA-617-Augmented [ 177 Lu]Lu-PSMA-617 Radioligand Therapy.

Authors: Burgard, Caroline Khreish, Fadi Dahlmanns, Lukas et al.

Source: Cancers. Oct2024, Vol. 16 Issue 20, p3532. 12p.

Analysis of Molecular Imaging and Laboratory Baseline Biomarkers in PSMA-RLT: Whole-Body Total Lesion PSMA (TLP) Predicts Overall Survival.

Authors: Hein, Connor Burgard, Caroline Blickle, Arne et al.

Source: Cancers. Aug2024, Vol. 16 Issue 15, p2670. 10p.

From Despair to Hope: First Arabic Experience of 177 Lu-PSMA and 161 Tb-PSMA Therapy for Metastatic Castration-Resistant Prostate Cancer.

Authors: Al-Ibraheem, Akram Abdlkadir, Ahmed Saad Sweedat, Deya' Aldeen et al.

Source: Cancers. Jun2024, Vol. 16 Issue 11, p1974. 19p.